Christopher Holler, PhD, Principal Scientist
Christopher helps lead the discovery efforts of the biology team for Arkuda’s FTD-GRN program, including developing novel assays to understand progranulin expression and function. Like many others, he’s been touched by the effects of neurodegenerative disease, having had a grandfather who suffered from Alzheimer’s disease for eight years before passing away. Seeing his grandfather’s personality change and memory of loved ones fade motivated Christopher to work toward developing impactful therapies to treat neurodegeneration.
Christopher has an extensive background in neurodegenerative diseases, possessing 12 years of experience studying Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). During his postdoctoral training at Emory University he studied the role of progranulin in lysosomes and explored therapeutic strategies to treat FTD-GRN.Back